Dose-dependent effectiveness of ketamine nebulisation in preventing post-operative sore throat due to tracheal intubation

M Reddy¹*, S Fiaz²
Professor¹*, Resident², Department of Anesthesiology
Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India.

Background: Sore throat is a common and distressing post-operative complication following endotracheal intubation that contributes to patient discomfort. Several pharmacological and non-pharmacological methods may be used to attenuate post-operative sore throat. In literature, there is no study evaluating dose-dependent effectiveness of ketamine nebulisation, neither has there been a study to assess patient acceptability with ketamine nebulisation. The prime objective of this study was to assess graded doses of ketamine nebulization in attenuation of post-operative sore throat and patient acceptability and satisfaction.

Materials and Methods: 90 patients between age group of 18 and 60yrs of ASA physical status 1 and 2 of either sex undergoing surgeries in supine position under general anaesthesia lasting for > 1hr, were randomly allocated into three groups. Group A received 0.5mg/kg, group B received 1mg/kg and group C received 1.5mg/kg body weight of nebulized preservative free ketamine for 15mins, 5mins before intubation. The patients were then assessed for acceptability to ketamine nebulization. At the end of the surgery post-operative sore throat was assessed at 0, 2, 4, 6, 8, 12 and 24hrs.

Results: Nebulized ketamine at a dose of 0.5mg/kg was comparatively less effective than 1 mg/kg and 1.5 mg/kg and the difference was statistically significant. 1mg/kg and 1.5mg/kg of nebulized ketamine are better and equally effective in reducing the incidence and severity of post-operative sore throat. There was no statistical difference in the acceptability scores to the different doses of nebulised ketamine.

Conclusion: Nebulized ketamine is well accepted by all patients and effective in reducing the severity of post-operative sore throat without any untoward effects. However larger population studies and estimation of serum ketamine levels is needed to find out a better dose of ketamine for nebulization to prevent the incidence and severity of post-operative sore throat.

Keywords: ketamine; nebulisation; post-operative sore-throat; dose-dependent

Introduction
Sore throat is a common post-operative complication following endotracheal intubation during general anaesthesia. Although post-operative sore throat is a self-limiting condition, it contributes to patient discomfort. The incidence of post-operative sore throat varies from 21 to 66%.

Localised trauma to the mucosa during laryngoscopy and intubation leads to aseptic inflammation of the pharyngeal mucosa leading to post-operative sore throat.

Many non-pharmacological and pharmacological methods have been tried to reduce the incidence and severity of post-operative sore throat. Using a small sized endotracheal tube, gentle laryngoscopy and intubation, maintaining cuff pressures not more
than 18-20cmH₂O, and local anaesthetics, steroids, NSAIDs, benzodamine gargle, ketamine gargle are some of the methods used by different authors with variable success.²,³

Ketamine, a phencyclidine derivative, has been used as a gargle or nebulization in the attenuation of post-operative sore throat by its action on peripheral NMDA receptors.⁴,⁵,⁶ In gargle form a large volume of the drug is used, hence patients are at risk of aspiration and it is difficult to perform. These complications can be avoided by using nebulized ketamine. A fixed dose of ketamine nebulisation 50mg in 5ml saline has been used in prevention of post-operative sore throat.²,⁷,⁸

In literature, there are no studies evaluating dose-dependent effectiveness of ketamine nebulisation, nor patient acceptability with ketamine nebulisation. The prime objective of this study was to assess graded doses of ketamine nebulization in attenuation of post-operative sore throat and patient acceptability and satisfaction.

Hence, we compared 0.5mg/kg, 1mg/kg and 1.5mg/kg dose of ketamine nebulisation in reducing the severity and incidence of post-operative sore throat.

**Material and methods**

After obtaining approval from the Institutional Ethics Committee, written informed consent was taken from 90 patients between age group of 18 and 60yrs of ASA physical status 1 and 2 of either sex undergoing surgeries in supine position under general anaesthesia lasting for more than one hour. Patients who were enrolled in the study were explained about the post-operative assessment of sore throat.

Patients with Mallampati class >2, pre-operative sore throat, allergy to study drug, recent history of NSAID medication, smokers, asthmatics, patients with COPD, weight > 80kgs, head and neck surgeries, those who require more than two attempts at intubation, surgeries requiring nasogastric tube and throat pack insertion were excluded from the study. Patients in whom extubation caused coughing or bucking were also excluded from the study.

Presuming the incidence of post-operative sore throat to be 65%, the power analysis (taking α=0.05 and β=0.90) calculated a sample size of 22 patients in each of the three groups to show a 50% reduction in the incidence. We chose to enroll 30 patients in each group.

Patients were randomly allocated into three groups of 30 patients each by a computer generated closed envelope technique in opaque sealed envelopes prepared by anaesthesiologist not part of the study. The envelopes were opened by the resident, and nebulisation solution was prepared according to group allocation. Group A received 0.5mg/kg, group B received 1mg/kg and group C received 1.5mg/kg body weight of nebulized preservative free ketamine (Aneket 50mg/ml, 2ml ampoule, Neon Laboratories Ltd.).

Baseline vital parameters were recorded. The study drug was diluted to 5ml and administered for 15mins through a compressed nebulizer. The resident later did not participate in the subsequent assessment of these patients. Patients were blinded as all the three solutions tasted the same.

Patients were assessed for the acceptability and satisfaction to ketamine nebulisation with acceptability score (Score 0 – Acceptable, Score 1- Not Acceptable due to either nebulisation or taste of the drug, Score 2 - Not Acceptable due to both nebulisation and taste).

Acceptability is defined as patients performing nebulization without any difficulty considered as acceptable and given a score of 0. If the patients complain of either bitter taste of the drug or difficulty in performing nebulization, were given a score of 1. Patients complaining of both bitter taste of the drug and difficulty in performing nebulization were given a score of 2.

Five minutes after nebulization patients were premedicated with glycopyrrolate 0.005 mg/kg, midazolam 0.02mg/kg, ondansetron 4mg i.v. Fentanyl 2mcg/kg was given as an analgesic followed by induction with propofol 2mg/kg and intubation was facilitated with vecuronium 0.1mg/kg i.v. Lignocaine 2% (preservative free) 1mg/kg was given i.v. 90secs before tracheal intubation.
Trachea was intubated with a sterile polyvinyl chloride cuffed endotracheal tube with an internal diameter of 7 to 7.5mm for female and 8 to 8.5mm for male patients. The cuff was inflated till no air leakage could be heard by auscultation over trachea and cuff pressure was maintained between 18 to 20cm H$_2$O measured by a handheld manometer. Anaesthesia was maintained with oxygen, nitrous oxide and isoflurane. Residual neuromuscular blockade was reversed with intravenous neostigmine 0.05mcg/kg and glycopyrrolate 0.01mg/kg. Lignocaine 2% (preservative free) 1mg/kg was given 90secs before extubation. Then the patient was extubated gently following suction under direct laryngoscopic vision, and once awake the patient was assessed for post-operative sore throat which was taken as 0 hours. This was followed by further assessments at 2, 4, 6, 8, 12 and 24hrs on a four-point scale: 0- No Sore Throat 1- Mild discomfort, mild sore throat (complains of sore throat only on asking) 2 - Moderate sore throat (complains of sore throat on his or her own) 3- Severe sore throat (associated with pain, change of voice or hoarseness) In between the assessment time intervals if the patients complain of sore throat, pain or hoarseness of voice on their own it was considered as score 2 or 3 that is moderate or severe sore throat depending upon the severity. Post-operative pain was managed with tramadol 50 mg i.v. 8hrly. For patients with severe sore throat rescue analgesia was given with paracetamol 1gm i.v. Patients were monitored for adverse effects such as nausea, vomiting, cough and dryness of mouth and treated accordingly.

**Results**

Of the 90 patients screened in our study, 9 patients were excluded from group A, B and C. Coughing and bucking was observed in 5 patients (2 in group A, 1 in group B and 2 in group C), 4 patients required more than 2 attempts for intubation (1 each in group A and C and 2 patients in group B).

The distribution of gender, ETT size (P=0.728, ANOVA test) in the three study groups was statistically not significant. Weight distribution in group A, B and C was 55.33±5.86, 58.22±4.32 and 54.52±4.16 kg respectively (P=0.016) by ANOVA test. (Table 1)

Table 1: Demographic data, ETT size distribution and duration of surgery in three groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>Group A (n=27)</th>
<th>Group B (n=27)</th>
<th>Group C (n=27)</th>
<th>P value</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (in years)</td>
<td>32.89±0.35</td>
<td>40.15±0.07</td>
<td>36.74±0.23</td>
<td>0.015</td>
<td>ANOVA test</td>
</tr>
<tr>
<td>Gender (F:M)</td>
<td>17:10</td>
<td>16:11</td>
<td>17:10</td>
<td>0.949</td>
<td>Chi-Square test</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>55.33±8.6</td>
<td>58.22±6.8</td>
<td>54.52±4.1</td>
<td>0.016</td>
<td>ANOVA test</td>
</tr>
<tr>
<td>ET tube size</td>
<td>7.61±0.56</td>
<td>7.72±0.53</td>
<td>7.70±0.56</td>
<td>0.72</td>
<td>ANOVA test</td>
</tr>
<tr>
<td>Duration of surgery</td>
<td>137.1±35.09</td>
<td>121.3±29.50</td>
<td>120.19±28.81</td>
<td>0.08</td>
<td>ANOVA test</td>
</tr>
</tbody>
</table>

Average dose distribution in three groups of patients studied was 27.89±2.86, 58.22±4.32 and 82.04±6.18 respectively (P<0.001, significant, ANOVA test).

All patients in group A, B and C were acceptable to ketamine nebulization (acceptability score 0). None of the patients in any study group had an acceptability score of 1 and 2. Acceptability Score distribution in three groups of patients studied is not significant by Fisher Exact test (P=1.000).

Table 2: Acceptability score distribution in three groups of patients studied

<table>
<thead>
<tr>
<th>Acceptability Score</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceptable</td>
<td>27(100%)</td>
<td>27(100%)</td>
<td>27(100%)</td>
<td>81(100%)</td>
</tr>
<tr>
<td>Discomfort due to nebulisation or taste of the drug</td>
<td>0(0%)</td>
<td>0(0%)</td>
<td>0(0%)</td>
<td>0(0%)</td>
</tr>
<tr>
<td>Discomfort due to both taste and nebulisation</td>
<td>0(0%)</td>
<td>0(0%)</td>
<td>0(0%)</td>
<td>0(0%)</td>
</tr>
<tr>
<td>Total</td>
<td>27(100%)</td>
<td>27(100%)</td>
<td>27(100%)</td>
<td>81(100%)</td>
</tr>
</tbody>
</table>
Table 3: Sore throat score distribution in three groups (Chi-Square test/Fisher Exact test)

<table>
<thead>
<tr>
<th>Sore Throat Score</th>
<th>0</th>
<th>2hrs</th>
<th>4hrs</th>
<th>6hrs</th>
<th>8hrs</th>
<th>12hrs</th>
<th>24hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group A (n=27)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>10</td>
<td>(37.0%)</td>
<td>8</td>
<td>(29.6%)</td>
<td>7</td>
<td>(25.9%)</td>
<td>8</td>
</tr>
<tr>
<td>Mild</td>
<td>14</td>
<td>(51.9%)</td>
<td>16</td>
<td>(59.3%)</td>
<td>19</td>
<td>(70.4%)</td>
<td>18</td>
</tr>
<tr>
<td>Moderate</td>
<td>3</td>
<td>(11.1%)</td>
<td>3</td>
<td>(11.1%)</td>
<td>1</td>
<td>(3.7%)</td>
<td>1</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Group B (n=27)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>21/77</td>
<td>(8%)</td>
<td>12/44.4</td>
<td>(4%)</td>
<td>7/25.9</td>
<td>(3%)</td>
<td>7/25.9</td>
</tr>
<tr>
<td>1</td>
<td>6/22</td>
<td>(22.2%)</td>
<td>15/55.6</td>
<td>(6%)</td>
<td>19/70.4</td>
<td>4/4%</td>
<td>20/74</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>1/3.7</td>
<td>(0%)</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Group C (n=27)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>23/85</td>
<td>(2%)</td>
<td>16/59.3</td>
<td>4%</td>
<td>12/44.4</td>
<td>4%</td>
<td>14/51.9</td>
</tr>
<tr>
<td>1</td>
<td>4/14.8</td>
<td>(6%)</td>
<td>11/40.7</td>
<td>7%</td>
<td>15/55.6</td>
<td>4%</td>
<td>15/48.1</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
<td>(0%)</td>
<td>0</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.001</td>
<td>0.062</td>
<td>0.435</td>
<td>0.120</td>
<td>0.047</td>
<td>0.032</td>
<td>0.032</td>
</tr>
</tbody>
</table>

At 0hrs, 37%, 77.8% and 85.2% patients did not have post-operative sore throat in group A, B and C respectively and the difference was statistically significant (P value <0.001).

At 4hrs, 7 patients (25.9%) had no sore throat, 19 patients (70.4%) had mild sore throat and 1 patient (3.7%) had moderate sore throat in both groups A and B; while in group C 12 patients (44.4%) had no sore throat, 15 patients (55.6%) had mild sore throat and none of the patients had severe sore throat.

At 12 and 24hrs not much difference was found in number of patients having post-operative sore throat in group B and C. 19 patients (70.4%) in group B and 21 patients (77.8%) in group C had no sore throat respectively. 8 patients (29.6%) and 6 patients (22.2%) had mild sore throat in group B and C respectively (P value 0.032). In group A, 12 patients (44.4%) had no sore throat and 15 patients (55.6%) had mild sore throat. (Table 3)

Except for thickened secretions in a few patients during extubation in group C no other untoward events were noted in all the study groups.

Discussion

Post-operative sore throat is a simple yet distressing complaint in several patients following endotracheal intubation. Ketamine decreases post-operative sore throat by its topical action on peripheral NMDA receptors as an anti-inflammatory and anti-nociceptive substance. Magnesium, an NMDA receptor antagonist has also been used prophylactically in prevention of post-operative sore throat.

In our study, there was no statistically significant difference in the distribution of age, gender, ET tube size and duration of surgery.

Chan, Rudra et al, Canbay et al, have observed that ketamine gargle is effective in attenuation of post-operative sore throat, however it is known to have a bitter taste and patients are at a risk for aspiration due to large volume of the drug. In contrast to this, Ahuja in her study stated that nebulised preservative free ketamine was tasteless which is in concurrence with our study. All the patients were comfortable with nebulization as the volume of the drug is less and easy to be administered. Nebulized ketamine is safer and easier to administer with better patient compliance.

Pneumatic nebulization produces large sized particles which get deposited in the mouth, throat during the process of nebulization hence reducing the incidence and severity of post-operative sore throat.

According to literature, all other studies have used a fixed dose of 50mg ketamine nebulization irrespective of patient body weight. Hence, we conducted a study to evaluate dose dependent effectiveness of ketamine nebulization in attenuation of post-operative sore throat and to
assess patient satisfaction and acceptability with ketamine nebulization.

In our study, at 0hrs 51.9% patients had mild sore throat and 11.1% patients had moderate sore throat in group A, while only 22.2% patients in group B and 14.8% patients in group C had mild sore throat. This difference was found to be statistically significant among the three study groups (P value <0.001). However, none of the patients in the three study groups experienced severe sore throat.

Monroe MC et al. showed post-operative sore throat is found to be peak at 2 to 4hrs. By this time the patients are completely conscious and more co-operative to participate in the study. In our study, we have observed maximum incidence of sore throat in group A at 4hrs (70.4%). Incidence of mild sore throat in group B and C at 4hs was 70.4% and 55.6% respectively. There is a gradual decrease in the incidence of sore throat at subsequent time intervals.

The incidence of mild sore throat at 24hrs was found to be 55.6% in group A, 29.6% in group B and 22.2% in group C. On comparing group A and B we observed that when the dose of ketamine is doubled the incidence of sore throat is almost halved.

Though the results in group C are better compared to group A and B at 0, 2, 4, 6 and 8hrs, the number of patients having no sore throat and mild sore throat in group B and C are comparable at 12 and 24hrs. Our results are comparable to a study by Jain et al in their nebulization group at 8 and 24hrs.

A study by Amingad, has shown fewer patients having no sore throat at 0 and 24hrs as compared to our study which could be attributed to the usage of 2% lignocaine local anaesthetic jelly applied over the endotracheal tube cuff and intra-operative i.v. dexamethasone used in their nebulized ketamine group.

Throughout the study period we found moderate sore throat in group A till 6hrs only and one patient had moderate sore throat in group B at 4hrs whereas no patients had moderate or severe sore throat in group C. Increasing doses of ketamine has shown to decrease both incidence and severity of sore throat.

None of the patients in the three study groups experienced severe sore throat at all time intervals hence no patients received paracetamol as rescue analgesia. This rescue analgesia will not affect subsequent assessment of sore throat because a study by Mishra J et al has shown that intravenous paracetamol decreased incidence of sore throat for up to 2hrs only.

We noted that there were increased and thicker secretions in patients who received 1.5 mg/kg dose of ketamine nebulization in our study. We have not measured the serum levels of ketamine and its metabolite norketamine to rule out systemic effects of the same.

Conclusion
Nebulized ketamine is well accepted by all patients and effective in reducing the severity of post-operative sore throat without any untoward effects. Nebulized ketamine at a dose of 0.5mg/kg was comparatively less effective than 1mg/kg and 1.5mg/kg and the difference was statistically significant. 1mg and 1.5mg/kg dose did not show much difference except increased and thickened secretions in 1.5mg/kg group. 1mg/kg and 1.5mg/kg of nebulized ketamine are better and equally effective in reducing the incidence and severity of post-operative sore throat. However larger population studies and estimation of serum ketamine levels is needed to find out a better dose of ketamine for nebulization to prevent the incidence and severity of post-operative sore throat.

Conflicts of interest
There are no conflicts of interest.

References:


